Loading…
Loading…
Arizona State Retirement System grew its position in Natera, Inc. (NASDAQ: NTRA) by 8.1% in the undefined quarter, according to its most recent filing with the SEC. The firm owned 38,604 shares of the medical research company's stock after buying an additional 2,899 shares during the period. Arizona State Retirement System's holdings in
Stanley Druckemiller holds some smaller positions in Amazon and Alphabet. His largest stockholding is a company called Natera, which does DNA diagnostics.
Healthcare is moving away from the traditional model of mass-produced, one-size-fits-all treatments toward individualized therapies. This evolution in medicine aims to provide treatments that are not only more effective but also carry a lower risk of adverse side effects by aligning with a patient's unique biology.
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of new data in Blood Neoplasia, validating the prognostic and predictive value of Signatera in patients with both newly diagnosed and relapsed/refractory (R/R) lymphoma. PET/CT scans serve as the standard tool for assessing treatment response in lymphoma, but their performance is limited, with positive predictive value (PPV) reported as low as 50%.
Caisse de depot et placement du Quebec bought a new position in Natera, Inc. (NASDAQ: NTRA) in the second quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 2,517 shares of the medical research company's stock, valued at approximately $683,000. A number of other institutional
The billionaire has good reasons to like this genetic testing leader.
NTRA teams with Angiex to use Signatera in a Phase 1 AGX101 trial, aiming to track ctDNA and deepen insights into treatment response.
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing and precision medicine, today announced a national partnership with Susan G. Komen®, the world's leading breast cancer organization. Together, the organizations aim to accelerate breast cancer awareness and education, including efforts to increase understanding of MRD. Natera's SignateraTM MRD test is supported by more than 185 peer-reviewed publications across multiple cancer types, including.